<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">563</article-id><article-id pub-id-type="doi">10.15690/vramn563</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ONCOLOGY: CURRENT ISSUES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ВОПРОСЫ ОНКОЛОГИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Degradome Components in Progression of Squamous Cell Carcinoma of the Head and Neck</article-title><trans-title-group xml:lang="ru"><trans-title>Компоненты системы деградома в прогрессии плоскоклеточных карцином головы и шеи</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kakurina</surname><given-names>Gelena Valer'evna</given-names></name><name xml:lang="ru"><surname>Какурина</surname><given-names>Гелена Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Cheif researcher</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, старший научный сотрудник</p></bio><email>kakurinagv@oncology.tomsk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kondakova</surname><given-names>Irina Viktorovna</given-names></name><name xml:lang="ru"><surname>Кондакова</surname><given-names>Ирина Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Head of the tumor biochemistry laboratory</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующий лабораторией биохимии опухолей</p></bio><email>kondakova@oncology.tomsk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Choynzonov</surname><given-names>Evgeniy Lkhamatsyrenovich</given-names></name><name xml:lang="ru"><surname>Чойнзонов</surname><given-names>Евгений Лхамацыренович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Academician of the Russian Academy of Sciences, Director of the Tomsk Cancer Research Institute</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор, академик РАН, директор Томского НИИ онкологии</p></bio><email>info@oncology.tomsk.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Tomsk Cancer Research Institute</institution></aff><aff><institution xml:lang="ru">ФГБНУ Томский научно-исследовательский институт онкологии</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2015-12-31" publication-format="electronic"><day>31</day><month>12</month><year>2015</year></pub-date><volume>70</volume><issue>6</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>684</fpage><lpage>693</lpage><history><date date-type="received" iso-8601-date="2015-12-06"><day>06</day><month>12</month><year>2015</year></date><date date-type="accepted" iso-8601-date="2015-12-06"><day>06</day><month>12</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2015, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2015, Издательство "Педиатръ"</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2017-01-27"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnikramn.spr-journal.ru/jour/about/submissions</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/563">https://vestnikramn.spr-journal.ru/jour/article/view/563</self-uri><abstract xml:lang="en"><p>The process of tumor progression is closely related to the intracellular, extracellular and intramembranous proteolysis. Many studies indicate that the proteases function as part of an extensive multidirectional network of proteolytic interactions. Disturbance of strictly controlled equilibrium of the proteolytic system is described in a number of diseases, including cancer. The paper presents a review of the available data concerning the contribution of intracellular, extracellular and intramembrane proteolysis to the process of squamous cell head and neck carcinoma. Specific mechanisms of interaction of different proteolytic systems in cancer progression both in general and in squamous cell head and neck carcinoma remain underinvestigated. The versatility of functions and complexity of the relationships between proteolytic systems highlights the importance of studying the participation of all degradome components in tumor progression that may clarify the multi-link complex mechanisms of carcinogenesis of squamous cell head and neck carcinoma and to identify markers of progression and/or a targets for therapeutic intervention.</p></abstract><trans-abstract xml:lang="ru"><p xml:lang="ru-RU">Все процессы опухолевой прогрессии тесно связаны с протеолитическими системами — внутриклеточными, внеклеточными, внутримембранными. Множество работ указывает на то, что протеазы функционируют как часть обширной многовекторной сети протеолитических взаимодействий. Нарушение строго контролируемого равновесия системы протеолиза описано при ряде заболеваний, включая онкологические. Статья посвящена обзору имеющихся в современной литературе данных о вкладе внутриклеточного, внеклеточного и внутримембранного протеолиза в процессы прогрессирования плоскоклеточного рака головы и шеи. Конкретные механизмы взаимодействия протеолитических систем разных уровней и локализаций при прогрессировании опухолевого процесса как в целом, так и при плоскоклеточном раке головы и шеи в частности остаются малоизвестными. Многогранность функций и сложность взаимосвязей протеолитических систем выдвигает на первый план важность изучения участия всех компонентов деградома в прогрессии опухоли, что может прояснить сложные многозвеньевые механизмы канцерогенеза плоскоклеточного рака головы и шеи и выявить возможные маркеры прогрессии и/или мишени для терапевтических воздействий.</p></trans-abstract><kwd-group xml:lang="en"><kwd>proteases</kwd><kwd>degradome</kwd><kwd>squamous head and neck cancer</kwd><kwd>metastasis</kwd><kwd>markers</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>протеазы</kwd><kwd>деградом</kwd><kwd>плоскоклеточный рак головы и шеи</kwd><kwd>метастазирование</kwd><kwd>маркеры</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1.	Чойнзонов ЕЛ, Балацкая ЛН, Кицманюк ЗД, Мухамедов МР, Дубский СВ. Реабилитация больных опухолями головы и шеи. Томск: Изд-во НТЛ. 2003. 296 c.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2.	Какурина ГВ, Кондакова ИВ, Чойнзонов ЕЛ. Постгеномные технологии в прогнозе метастазирования плоскоклеточных карцином головы и шеи. Российский биотерапевтический журнал. 2011;10(3):31–36.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3.	Какурина ГВ, Кондакова ИВ, Чойнзонов ЕЛ. Прогнозирование метастазирования плоскоклеточных карцином головы и шеи. Вопросы онкологии. 2012;58(1):26–32.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4.	Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239–252. doi: 10.1038/nrc2618</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5.	Mason SD, Joyce JA. Proteolytic networks in cancer. Trends Cell Biol. 2011;21(4):228–237.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.	Edwards D. The Cancer Degradome: Proteases and Cancer Biology. New York, London: Springer. 2008. 926 p. doi: 10.1007/978-0-387-69057-5</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7.	Ugalde AP, Ordóez GR, Quirós PM. Puente XS, López-Otín C. Metalloproteases and the degradome. Methods Mol Biol. 2010;622:3–29. doi: 10.1007/978-1-60327-299-5_1</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8.	Клишо ЕВ, Кондакова ИВ, Чойнзонов ЕЛ, Черемисина ОВ, Чижевская СЮ, Шишкин ДА. Прогностическая значимость определения металлопротеиназ и их тканевых ингибиторов у больных плоскоклеточным раком органов головы и шеи. Онкохирургия. 2011;3(1):17–22.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9.	Спирина ЛВ, Кондакова ИВ, Клишо ЕВ, Какурина ГВ, Шишкин ДА. Металлопротеиназы как регуляторы неоангиогенеза в злокачественных новообразованиях. Сибирский онкологический журнал. 2007;1:67–71.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10.	Lemberg MK, Freeman M. Functional and evolutionary implications of enhanced genomic analysis of rhomboid intramembrane proteases. Genome Res. 2007;17(11):1634–1646. doi: 10.1101/gr.6425307</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11.	Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated Intramembrane Proteolysis: A Control Mechanism Conserved from Bacteria to Humans. Cell. 2000;100(4):391–398.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12.	Lemberg MK. Intramembrane Proteolysis in Regulated Protein Trafficking. Traffic. 2011;12(9):1109–1118. doi: 10.1111/j.1600-0854.2011.01219.x</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13.	Magdolen V. Novel cancer related biomarkers. In: Kallikrein related peptidases. Ed. V Magdolen, CP. Sommerhoff, F Hans, S Manfred. Berlin: Walter de Gruyter. 2012. Р. 226.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14.	Welman A, Sproul D, Mullen P, Muir M, Kinnaird AR, Harrison DJ, Faratian D, Brunton VG, Frame MC. Diversity of Matriptase Expression Level and Function in Breast Cancer. PLoS ONE. 2012;7(4):e34182. doi: 10.1371/journal.pone.0034182</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15.	Kawaguchi M, Kataoka H. Mechanisms of Hepatocyte Growth Factor Activation in Cancer Tissues. Cancers. 2014;6(4):1890–1904. doi: 10.3390/cancers6041890</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16.	Cheng MF, Huang MS, Lin CS, Lin LH, Lee HS, Jiang JC, Hsia KT. Expression of matriptase correlates with tumour progression and clinical prognosis in oral squamous cell carcinoma. Histopathology. 2014;65(1):24–34.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17.	Szabo R, Rasmussen AL, Moyer AB, Kosa P, Schafer JM, Molinolo AA, Gutkind JS, Bugge TH. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene. 2011;30(17):2003–2016. doi: 10.1038/onc.2010.586</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18.	Lyons JG, Patel V, Roue NC, Fok SY, Soon LL, Halliday GM, Gutkind JS. Snail up-regulates proinflammatory mediators and inhibits differentiation in oral keratinocytes. Cancer Res. 2008;68(12):4525–4530. doi: 10.1158/1078-0432.CCR-07-6735</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19.	Sales KU, Friis S, Konkel JE, Godiksen S, Hatakeyama M, Hansen KK, Rogatto SR, Szabo R, Vogel LK, Chen W, Gutkind JS, Bugge TH. Non-hematopoietic PAR-2 is essential for matriptase driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis. Oncogene. 2015;34(3):346–356. doi: 10.1038/onc.2013.563</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20.	Алейник АН, Кондакова ИВ. Сигнальная система notch и онкогенез. Вопросы онкологии. 2012;58(5):593–596.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21.	Gridley T. Notch signaling in vascular development and physiology. Development. 2007;134(15):2709–2718 doi: 10.1242/dev.004184</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22.	Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, de Strooper B, Hartmann D, Saftig P. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and β-catenin translocation. Proc Natl Acad Sci USA. 2005;102(26):9182–9187 doi: 10.1073/pnas.0500918102</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23.	Zielinski V, Brunner M, Heiduschka G, Schneider S, Seemann R, Erovic B, Thurnher D. ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study. BMC Cancer. 2012;12:76. doi: 10.1186/1471-2407-12-76</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24.	Rao VH, Kandel A, Lynch D, Pena Z, Marwaha N, Deng C, Watson P, Hansen LA. A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion. Oncogene. 2012;31(23):2888–28898 doi: 10.1038/onc.2011.460</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25.	Boulton ME, Cai J, Grant MB. Gamma-Secretase: a multifaceted regulator of angiogenesis. J Cell Mol Med. 2008;12(3):781–795. doi: 10.1111/j.1582-4934.2008.00274.x</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>26.	Egloff AM, Grandis JR. Molecular Pathways: Context dependent approaches to Notch targeting as cancer therapy. Clin Cancer Res. 2012;18(19):5188–5195. doi: 10.1158/1078-0432.CCR-11-2258</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>27.	Romanic AM, Burns-Kurtis CL, Ao Z, Arleth AJ, Ohlstein EH. Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients. Am J Physiol Renal Physiol. 2001;281(2):F309–317.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>28.	Рогова ЛН, Шестернина НВ, Замечник ТВ, Фастова ИА. Матриксные металлопротеиназы, их роль в физиологических и патологических процессах. Вестник новых медицинских технологий. 2011;ХVIII(2):86.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>29.	Murphy DA and Courtneidge SA. The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol. 2011;12(7):413–426. doi: 10.1038/nrm3141</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>30.	Ratnikov BI, Rozanov DV, Postnova TI, Baciu PG, Zhang H, DiScipio RG, Chestukhina GG, Smith JW, Deryugina EI, Strongin AY. An Alternative Processing of Integrin αv subunit in tumor cells by membrane type-1 matrix metalloproteinase. Journal of Biological Chemistry. 2002;277:7377–7385. doi: 10.1074/jbc.M109580200</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>31.	Albrechtsen R, Kveiborg M. ADAM12 redistributes and activates MMP-14, resulting in gelatin degradation, reduced apoptosis and increased tumor growth. J Cell Sci. 2013;126(P20):4707–4720. doi: 10.1242/jcs.129510</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>32.	Берман АЕ, Козлова НИ, Морозевич ГЕ. Интегрины как потенциальная мишень для целевой терапии рака. Биомедицинская химия. 2013;59(3):239–248.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>33.	Спирина ЛВ, Кондакова ИВ. Миграция клеток и онкогенез. Российский онкологический журнал. 2010;3:49–53.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>34.	Machesky LM. Lamellipodia and filopodia in metastasis and invasion. FEBS. 2008;582(14):2102–2111. doi: 10.1016/j.febslet.2008.03.039</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>35.	Yu X, Zech T, McDonald L, Gonzalez EG, Li A, Macpherson I, Schwarz JP, Spence H, Futó K, Timpson P, Nixon C, Ma Y, Anton IM, Visegrády B, Insall RH, Oien K, Blyth K, Norman JC, Machesky LM. N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. JCB. 2012;199(3):527–544. doi: 10.1083/jcb.201203025</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>36.	Miyazawa Y, Uekita T, Ito Y, Seiki M, Yamaguchi H, Sakai R. CDCP1 regulates the function of MT1-MMP and invadopodia mediated invasion of cancer cells. Mol Cancer Res. 2013;11(6):628–637. doi: 10.1158/1541-7786.MCR-12-0544</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>37.	Poincloux R, Lizarraga F, Chavrier P. Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci. 2009;122(Pt.17):3015–3024. doi: 10.1242/jcs.034561</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>38.	Akanuma N, Hoshino I, Akutsu Y, Murakami K, Isozaki Y, Maruyama T, Yusup G, Qin W, Toyozumi T, Takahashi M, Suito H, Hu X, Sekino N, Matsubara H. MicroRNA-133a regulates the mRNAs of two invadopodia related proteins, FSCN1 and MMP14, in esophageal cancer. Br J Cancer. 2014;110(1):189–198. doi: 10.1038/bjc.2013.676</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>39.	Малахова ЕВ, Кондакова ИВ, Черемисина ОВ, Какурина ГВ, Меньшиков КЮ. Экспрессия генов матриксных металлопротеиназ и их тканевых ингибиторов в тканях опухолей у больных раком гортани и гортаноглотки. Сибирский онкологический журнал. 2012;1:36–40.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>40.	Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S. Expressions of matrix metalloproteinases in early stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res. 2004;10:634–640. doi: 10.1158/1078-0432.CCR-0864-02</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>41.	Клишо ЕВ, Кондакова ИВ, Чойнзонов ЕЛ, Васильева ОС. Прогностическая значимость протеаз у больных плоскоклеточными карциномами головы и шеи. Сибирский научный медицинский журнал. 2005;25(2):82–91.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>42.	Gu Y, Lee W, Shena J. Site-2 protease responds to oxidative stress and regulates oxidative injury in mammalian cells. Sci Rep. 2014;4:6268. doi: 10.1038/srep06268</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>43.	Rosenblat M, Draganov D, Watson CE, Bisgaier CL, La Du BN, Aviram M. Mouse macrophage paraoxonase-2 activity is increased whereas cellular paraoxonase-3 activity is decreased under oxidative stress. Arterioscler Thromb Vasc Biol. 2003;23:468–474. doi: 10.1161/01.ATV.0000059385.95664.4D</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>44.	Кондакова ИВ, Какурина ГВ, Смирнова ЛП, Борунов ЕВ. Регуляция пролиферации и апоптоза опухолевых клеток свободными радикалами. Сибирский онкологический журнал. 2005;1:58–61.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>45.	Кондакова ИВ, Загребельная ГВ. Влияние комбинации пероксидных радикалов с оксидом азота на синтез ДНК в опухолевых клетках. Биомедицинская химия. 2004;50(6):576–582.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>46.	Freeman M. Rhomboid proteases and their biological functions. Annu Rev Genet. 2008;42:191–210. doi: 10.1146/annurev.genet.42.110807.091628</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>47.	Cheng TL, Lai CH, Jiang SJ, Hung JH, Liu SK, Chang BI, Shi GY, Wu HL. RHBDL2 Is a Critical Membrane Protease for Anoikis Resistance in Human Malignant Epithelial Cells. Scientific World Journal. 2014;2014:ID 902987.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>48.	Zou H, Thomas SM, Yan ZW, Grandis JR, Vogt A, Li LY. Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. FASEB J. 2009;23(2):425–432. doi: 10.1096/fj.08-112771</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>49.	Spirina LV, Yunusova NV, Kondakova IV, Kolomiets LA, Koval VD, Chernyshova AL, Shpileva OV. Association of growth factors, HIF-1 and NF-κB expression with proteasomes in endometrial cancer. Molecular Biology Reports. 2012;39:8655–8662. doi: 10.1007/s11033-012-1720-y</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>50.	Спирина ЛВ, Кондакова ИВ. Роль внутриклеточного спе-цифического протеолиза в онкогенезе. Вопросы онкологии. 2008;54(6):690–694.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>51.	Спирина ЛВ, Кондакова ИВ, Чойнзонов ЕЛ, Шарова НП, Чижевская СЮ, Шишкин ДА. Активность и субъединичный состав протеасом в плоскоклеточных карциномах головы и шеи. Бюллетень экспериментальной биологии и медицины. 2010;149(1):89–92.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>52.	Spirina LV, Kondakova IV, Choynzonov EL, Chigevskaya SY, Shishkin DA, Kulbakin DY. Expression of vascular endotelian growth factor and transcription factors HIF-1, NF-KB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities. J Cancer Res Clin Oncol. 2013;139:625–633. doi: 10.1007/s00432-012-1366-0</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>53.	Zheng M, McKeown-Longo PJ. Cell adhesion regulates Ser/Thr phosphorylation and proteasomal degradation of HEF1. J Cell Sci. 2006;119(Pt.1):96–103. doi: 10.1242/jcs.02712</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>54.	Lucas JT Jr., Salimath BP, Slomiany MG, Rosenzweig SA. Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene. 2010;29(31):4449–4459. doi: 10.1038/onc.2010.185</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>55.	Какурина ГВ, Кондакова ИВ, Чойнзонов ЕЛ, Шишкин ДА, Черемисина ОВ. Особенности протеома сыворотки крови больных плоскоклеточными карциномами головы и шеи. Сибирский онкологический журнал. 2013;2(56):62–66.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>56.	Pop C, Salvesen GS. Human Caspases: Activation, Specificity, and Regulation. J Biol Chem. 2009;284:21777–21781. doi: 10.1074/jbc.R800084200</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>57.	Miura M. Apoptotic and nonapoptotic caspase functions in animal development. Cold Spring Harb Perspect Biol. 2012;4(10). doi: 10.1101/cshperspect.a008664</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>58.	Li C, Egloff AM, Sen M, Grandis JR, Johnson DE. Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Mol Oncol. 2014;8(7):1220–1230. doi: 10.1016/j.molonc.2014.03.018</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>59.	Harrison LB. Head and Neck Cancer: A Multidisciplinary Approach. Ed. Louis BH, Roy BS, Waun KH. 2013. NY: Lippincott Williams &amp; Wilkins. 2004. 1077 р.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>60.	Palavalli MH, Natarajan SS, Wang TT, Krishnan HB. Imbibition of Soybean Seeds in Warm Water Results in the Release of Copious Amounts of Bowman Birk Protease Inhibitor, a Putative Anticarcinogenic Agent. J Agric Food Chem. 2012;60(12):3135–3143. doi: 10.1021/jf205308w</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>61.	Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL Jr. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila). 2013;6(5):410–418. doi: 10.1158/1940-6207.CAPR-13-0004</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>62.	Кондакова ИВ, Клишо ЕВ, Савенкова ОВ, Шишкин ДА, Чойнзонов ЕЛ. Патогенетическая значимость системы матриксных металлопротеиназ при плоскоклеточном раке головы и шеи. Сибирский онкологический журнал. 2011;1:29–33.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>63.	Gilles C, Polette M, Coraux C. Contribution of MT1-MMP and of human laminin-5 γ2 chain degradation to mammary epithelial cell migration. J Cell Sci. 2001;114:2967–2976.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>64.	Мнихович МВ, Циперович К, Яхонсон М, Гитерман Ц, Гаврилюк АА, Фомина ЛВ, Гуминский ЮИ, Вернигородский СВ, Тернов ММ, Мигляс ВГ. Межклеточные взаимодействия при инвазии клеток: морфологические и молекулярно-биологические особенности. Вісник морфології. 2013;19(1):198–208.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>65.	Jiao Y, Feng X, Zhan Y. Wang R, Zheng S, Liu W, Zeng X. Matrix metalloproteinase-2 Promotes αvβ3 Integrin Mediated Adhesion and Migration of Human Melanoma Cells by Cleaving Fibronectin. PLoS One. 2012;7(7):e41591. doi: 10.1371/journal.pone.0041591</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>66.	Nawrocki-Raby B, Gilles Ch, Polette M, Martinella-Catusse C, Bonnet N, Puchelle E, Foidart JM, Van Roy F, Birembaut P. E-Cadherin Mediates MMP Down-Regulation in Highly Invasive Bronchial Tumor Cells. Am J Pathol. 2003;163(2):653–661. doi: 10.1016/S0002-9440(10)63692-9</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>67.	Kessenbrock K, Plaks V, Werb Z. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell. 2010;141(1):52–67. doi: 10.1016/j.cell.2010.03.015</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>68.	Xie SS, Hu F, Tan M, Duan YX, Song XL, Wang CH. Relationship between expression of matrix metalloproteinase-9 and adenylyl cyclase-associated protein 1 in chronic obstructive pulmonary disease. J Int Med Res. 2014;42(6):1272–1284. doi: 10.1177/0300060514548290</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>69.	Hu Y, Xu S, Jin W, Yi Q, Wei W. Effect of the PTEN gene on adhesion, invasion and metastasis of osteosarcoma cells. Oncol Rep. 2014;32(4):1741–1747. doi: 10.3892/or.2014.3362</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>70.	Какурина ГВ, Кондакова ИВ, Черемисина ОВ, Шишкин ДА, Чойнзонов ЕЛ. Аденилил-циклаза-ассоциированный протеин-1 в развитии плоскоклеточных карцином головы и шеи. Бюллетень экспериментальной биологии и медицины. 2015;160(11):648–651.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>71.	Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002;115(Pt.19):3719–3727. doi: 10.1242/jcs.00063</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>72.	Sawicki G. Intracellular regulation of matrix metalloproteinase-2 activity: new strategies in treatment and protection of heart subjected to oxidative stress. Scientifica (Cairo). 2013;2013:130451. doi: 10.1155/2013/130451. doi: 10.1155/2013/130451</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>73.	Hockenbery DM. MMPs in Unusual Places. Am J Pathol. 2006;169:1101–1103. doi: 10.2353/ajpath.2006.060553</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>74.	Кондакова ИВ, Какурина ГВ, Спирина ЛВ, Черемисина ОВ, Шишкин ДА. Оценка внеклеточного и внутриклеточного протеолиза при предопухолевых и опухолевых заболеваниях гортани. Сибирский онкологический журнал. 2014;3:45–50.</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>75.	Awasthi N, Wang-Su ST, Wagner BJ. Downregulation of MMP-2 and 9 by proteasome inhibition: a possible mechanism to decrease LEC migration and prevent posterior capsular opacification. Invest. Ophthalmol Vis. Sci. 2008;49(5):1998–2003. doi: 10.1167/iovs.07-0624</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>76.	Popp O, Heidinger M, Ruiz-Heinrich L. The calpastatinderived calpain inhibitor CP1B reduces mRNA expression of matrix metalloproteinase-2 and 9 and invasion by leukemic THP-1 cells. Biol Chem. 2003;384:951–958. doi: 10.1515/BC.2003.107</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>77.	Jin X, Yagi M, Akiyama N, Hirosaki T, Higashi S, Lin CY, Dickson RB, Kitamura H, Miyazaki K. Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci. 2006;97(12):1327–1334. doi: 10.1111/j.1349-7006.2006.00328.x</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>78.	Uhland K. Matriptase and its putative role in cancer. Cell Mol Life Sci. 2006;63(24):2968–2978. doi: 10.1007/s00018-006-6298-x</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>79.	Milner JM, Patel A, Davidson RK, Swingler TE, Desilets A, Young DA Kelso EB, Donell ST, Cawston TE, Clark IM, Ferrell WR, Plevin R, Lockhart JC, Leduc R, Rowan AD. Matriptase is a novel initiator of cartilage matrix degradation in osteoarthritis. Arthritis Rheum. 2010;62(7):1955–1966. doi: 10.1002/art.27476</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>80.	Domoto T, Takino T, Guo L, Sato H. Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase. Cancer Sci. 2012;103(3):448–455. doi: 10.1111/j.1349-7006.2011.02162.x</mixed-citation></ref></ref-list></back></article>
